InMed Pharmaceuticals Inc. (INM): restructuring charge — InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline

InMed Pharmaceuticals Inc.

Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.
Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.
Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.
Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

InMed Pharmaceuticals Inc. announced a restructuring with charges of severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 affecting BayMedica LLC commercial operations business segment.

Type: restructuring
Charge: severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000
Affected area: BayMedica LLC commercial operations business segment

Exact text from the filing

In connection with the wind down of commercial operations, BayMedica is expected to incur severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 through the end of the fiscal year.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-024752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.